ABBV Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$278.61median target· current $264.02 (+5.5%)31 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
31 articles · sorted by datePage 1 of 2 · 31 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio74.10Forward 16.21
EPS (TTM)$3.55290.4% YoY
Profit margin9.8%HEALTHCARE
Market cap$464.82BMega cap
Valuation
- Forward P/E
- 16.21
- PEG ratio
- 0.54
- P/B
- 50.46
- P/S (TTM)
- 7.22
- EV/EBITDA
- 27.04
Profitability & growth
- ROE (TTM)
- 62.3%
- Operating margin
- 40.0%
- Revenue growth YoY
- 10.2%
- Dividend yield
- 2.6%
- Beta
- 0.28
Last earnings
Jul 31, 2026 · Estimate $3.64 · Reported $3.65
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About AbbVie Inc
Company profileAbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$464.82B
Shares outstanding$1.77B
52W high$267.47
52W low$189.40
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent